Wedbush: Y-mAbs Could Attract Investor Attention As Market Volatility Grows
Bluebird Bio's Near-Term Product Launches Pose Risks, Wedbush Says In Downgrade
Wedbush: Trajectory For Stemline Therapeutics' Blood Cancer Drug Priced Into Stock
FDA Delays Selinexor Approval By 3 Months — So Why Is Karyopharm Ripping Higher?
David Nierengarten Recent News
Analysts Slash KaryoPharm Price Targets By Over 50% After Adcom Setback
Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?
Wedbush Moves To The Sidelines On Tesaro Following Glaxo Deal
Wedbush Bets On Magenta Therapeutics, Projects Rewards If Stem Cell Technology Successful
'We Expect A Quick Resolution': Despite Partial Clinical Hold On Epizyme's Drug Candidate, Wedbush Stays Bullish
Analyst: Spark Therapeutics' $850K Blindness Drug Has Smaller-Than-Expected Market
Wedbush Rates Kura Oncology Outperform As Catalysts Loom
Endocyte Shares Up More Than 100% In 2 Days, But Analyst Sees Even More Upside Possible
A Data-Rich Year Has Analysts Accepting Their Fate Therapeutics Trade
Wedbush Cuts TESARO Target By 18% Following SOLO-2 Results
Wedbush Asks: How Does Kite Pharma's ZUMA-1 Compare To Juno's TRANSCEND?
Bluebird Bio Shares Could See Value Fly To $95 As 2017 Will Be A 'Catalyst-Filled Year'
Analyst Breaks Down Bluebird Bio's Better-Than-Expected Clinical Results
Good And Bad News from Epizyme; Wedbush Analyst Weighs In
Tailwinds Continue To Hold The Street's Gaze Toward Bluebird Bio Aloft
Wedbush Raises TESARO Price Target From $107 To $139
Audentes Therapeutics Initiated Overweight At Wedbush
Bluebuird Bio Crashes Nearly 30%: What's Next?
How Wedbush Sees The Alexion–Synageva Deal